Drug
Ibrutinib
Ibrutinib: highest development phase Phase 2, developed by AbbVie, Roche. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AbbVie, Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ibrutinib NCT02436707 | Phase 2 | Lymphoma |
| Ibrutinib NCT02956382 | Phase 1/2 | Refractory Follicular Lymphoma |
Latest
No recent events.
Follow Ibrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.